Sentinox: meta-analysis of COVID-19 studies

All studies Serious outcomes Viral clearance RCTs Peer-reviewed All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)37%

Viral clearance (1)29%

RCTs (1)37%

Early (1)37%

00.511.5+

← Sentinox
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

Sentinox COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Panatto (RCT)37%0.63 · 0.12–3.38progression2/203/19

Early treatment37%0.63 · 0.12–3.382/203/1937% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.61

All studies37%0.63 · 0.12–3.382/203/1937% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.6100.511.52+

Rotate screen for more detailsIncrease width for more details

← Sentinox
reduces riskSentinox
increases risk →

c19early.org

October 2026

Sentinox COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Panatto (RCT)37%0.63 · 0.12–3.38progression2/203/19

Early treatment37%0.63 · 0.12–3.382/203/1937% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.61

All studies37%0.63 · 0.12–3.382/203/1937% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.6100.511.52+

Rotate screen for more detailsIncrease width for more details

← Sentinox
reduces riskSentinox
increases risk →

c19early.org

October 2026

Sentinox COVID-19 viral clearance results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Panatto (RCT)29%0.71 · 0.54–0.93viral+34 (n)15 (n)

Early treatment29%0.71 · 0.54–0.9334 (n)15 (n)29% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.012

All studies29%0.71 · 0.54–0.9334 (n)15 (n)29% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.01200.511.52+

Rotate screen for more detailsIncrease width for more details

← Sentinox
reduces riskSentinox
increases risk →

c19early.org

October 2026

Sentinox COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Panatto (RCT)37%0.63 · 0.12–3.38progression2/203/19

Early treatment37%0.63 · 0.12–3.382/203/1937% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.61

All studies37%0.63 · 0.12–3.382/203/1937% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.6100.511.52+

Rotate screen for more detailsIncrease width for more details

← Sentinox
reduces riskSentinox
increases risk →

c19early.org

October 2026

Sentinox COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Panatto (RCT)37%0.63 · 0.12–3.38progression2/203/19

Early treatment37%0.63 · 0.12–3.382/203/1937% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.61

All studies37%0.63 · 0.12–3.382/203/1937% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.6100.511.52+

Rotate screen for more detailsIncrease width for more details

← Sentinox
reduces riskSentinox
increases risk →

c19early.org

October 2026

Sentinox COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Panatto (RCT)37%0.63 · 0.12–3.38progression2/203/19 Panatto (RCT)85%0.15 · 0.01–2.65progression0/183/19 Panatto (RCT)67%0.33 · 0.06–1.83progression2/383/19 Panatto (RCT)29%0.71 · 0.54–0.93viral+34 (n)15 (n) Panatto (RCT)30%0.70 · 0.56–0.88viral+34 (n)15 (n)

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Sentinox
reduces riskSentinox
increases risk →